Molecular Tumor Boards Improve Survival in Refractory Solid Tumors : The Oncologist | May 2026

Introduction

Precision oncology has transformed cancer care through the integration of genomic profiling and targeted therapies. However, translating complex next-generation sequencing data into clinically actionable treatment strategies remains difficult in patients with refractory solid tumors, particularly after multiple prior treatment failures. Molecular tumor boards (MTBs) have emerged as multidisciplinary platforms designed to bridge this gap by integrating genomic, clinical and therapeutic expertise.

Problem Statement

Although MTBs are increasingly implemented in oncology practice, real-world evidence demonstrating meaningful survival benefit remains limited, especially in heavily pretreated and biologically heterogeneous patient populations. A major unanswered question is whether adherence to MTB-recommended therapies truly improves clinical outcomes beyond the mere identification of actionable molecular alterations.

Summary

This large real-world study demonstrates that MTB-guided treatment strategies can significantly improve survival outcomes in patients with refractory solid tumors. Patients who received therapies matched to MTB recommendations experienced markedly prolonged overall survival and progression-free survival compared with patients who either did not receive recommended therapies or had no actionable molecular alterations. Importantly, the study suggests that the clinical benefit was not simply due to the presence of actionable genomic findings, but rather the successful translation of these findings into individualized treatment decisions through multidisciplinary interpretation. The MTB framework incorporated not only genomic alterations but also tumor biology, prior therapies, organ function, immunotherapy biomarkers and overall patient condition to guide precision treatment selection. The survival advantage remained consistent even among patients receiving immunotherapy-based regimens, highlighting the broader value of integrated molecular decision-making beyond targeted therapies alone. Notably, many patients had undergone multiple previous treatment lines, emphasizing the potential role of MTBs in highly refractory disease settings where standard therapeutic options are exhausted. The study also reinforces the growing relevance of tier 2 genomic alterations and combinatorial biomarker interpretation in modern oncology. Overall, these findings support the expanding role of multidisciplinary molecular oncology programs as a critical component of precision cancer care and demonstrate that structured MTB-guided treatment selection can meaningfully influence real-world oncologic outcomes.